CAR T-cell Therapy Impresses in Multiple Myeloma.
CAR T cells that target the B-cell maturation antigen produce remissions in patients with relapsed or refractory multiple myeloma. Updated results from a phase I study suggest that 94% of patients treated with the highest doses showed complete or partial remissions and high rates of progression-free survival.